Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Inhibition of breast cancer metastasis suppressor 1 promotes a mesenchymal phenotype in lung epithelial cells that express oncogenic K-RasV12 and loss of p53.

Hall EH, Liu Y, Xiao A, Shock L, Brautigan DL, Mayo MW, Adusumilli PS, Jones DR.

PLoS One. 2014 Apr 24;9(4):e95869. doi: 10.1371/journal.pone.0095869. eCollection 2014.

2.

Loss of BRMS1 promotes a mesenchymal phenotype through NF-κB-dependent regulation of Twist1.

Liu Y, Mayo MW, Xiao A, Hall EH, Amin EB, Kadota K, Adusumilli PS, Jones DR.

Mol Cell Biol. 2015 Jan;35(1):303-17. doi: 10.1128/MCB.00869-14. Epub 2014 Nov 3.

3.

Breast cancer metastasis suppressor 1 (BRMS1) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer.

Smith PW, Liu Y, Siefert SA, Moskaluk CA, Petroni GR, Jones DR.

Cancer Lett. 2009 Apr 18;276(2):196-203. doi: 10.1016/j.canlet.2008.11.024. Epub 2008 Dec 25.

4.

TSPAN2 is involved in cell invasion and motility during lung cancer progression.

Otsubo C, Otomo R, Miyazaki M, Matsushima-Hibiya Y, Kohno T, Iwakawa R, Takeshita F, Okayama H, Ichikawa H, Saya H, Kiyono T, Ochiya T, Tashiro F, Nakagama H, Yokota J, Enari M.

Cell Rep. 2014 Apr 24;7(2):527-38. doi: 10.1016/j.celrep.2014.03.027. Epub 2014 Apr 13.

5.

Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1.

Zhang S, Lin QD, DI W.

Int J Gynecol Cancer. 2006 Mar-Apr;16(2):522-31.

PMID:
16681721
6.

Wild-type and mutant p53 differentially regulate NADPH oxidase 4 in TGF-β-mediated migration of human lung and breast epithelial cells.

Boudreau HE, Casterline BW, Burke DJ, Leto TL.

Br J Cancer. 2014 May 13;110(10):2569-82. doi: 10.1038/bjc.2014.165. Epub 2014 Apr 8.

7.

Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations.

Sato M, Larsen JE, Lee W, Sun H, Shames DS, Dalvi MP, Ramirez RD, Tang H, DiMaio JM, Gao B, Xie Y, Wistuba II, Gazdar AF, Shay JW, Minna JD.

Mol Cancer Res. 2013 Jun;11(6):638-50. doi: 10.1158/1541-7786.MCR-12-0634-T. Epub 2013 Feb 28.

8.

Loss of giant obscurins from breast epithelium promotes epithelial-to-mesenchymal transition, tumorigenicity and metastasis.

Shriver M, Stroka KM, Vitolo MI, Martin S, Huso DL, Konstantopoulos K, Kontrogianni-Konstantopoulos A.

Oncogene. 2015 Aug 6;34(32):4248-59. doi: 10.1038/onc.2014.358. Epub 2014 Nov 10.

9.

Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer.

Guo BH, Feng Y, Zhang R, Xu LH, Li MZ, Kung HF, Song LB, Zeng MS.

Mol Cancer. 2011 Jan 28;10(1):10. doi: 10.1186/1476-4598-10-10.

10.
11.

Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.

Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames DS, Girard L, Soh J, Sato M, Iwasaki Y, Ishizuka T, Gazdar AF, Minna JD, Mori M.

Oncogene. 2013 Aug 22;32(34):4034-42. doi: 10.1038/onc.2012.402. Epub 2012 Sep 10.

12.

Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors.

Symonds JM, Ohm AM, Carter CJ, Heasley LE, Boyle TA, Franklin WA, Reyland ME.

Cancer Res. 2011 Mar 15;71(6):2087-97. doi: 10.1158/0008-5472.CAN-10-1511. Epub 2011 Feb 18.

13.

BRMS1 regulates apoptosis in non-small cell lung cancer cells.

You J, He X, Ding H, Zhang T.

Cell Biochem Biophys. 2015 Jan;71(1):465-72. doi: 10.1007/s12013-014-0226-8.

PMID:
25182004
14.

Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition.

Sun M, Liu XH, Wang KM, Nie FQ, Kong R, Yang JS, Xia R, Xu TP, Jin FY, Liu ZJ, Chen JF, Zhang EB, De W, Wang ZX.

Mol Cancer. 2014 Mar 21;13:68. doi: 10.1186/1476-4598-13-68.

15.

Hepatocyte nuclear factor 6 suppresses the migration and invasive growth of lung cancer cells through p53 and the inhibition of epithelial-mesenchymal transition.

Yuan XW, Wang DM, Hu Y, Tang YN, Shi WW, Guo XJ, Song JG.

J Biol Chem. 2013 Oct 25;288(43):31206-16. doi: 10.1074/jbc.M113.480285. Epub 2013 Sep 10.

16.

Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.

Vatan O, Bilaloglu R, Tunca B, Cecener G, Gebitekin C, Egeli U, Yakut T, Urer N.

Tumori. 2007 Sep-Oct;93(5):473-7.

17.

Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells.

Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, Kamer I, Stambolsky P, Shelly A, Goldfinger N, Valsesia-Wittmann S, Puisieux A, Zundelevich A, Gal-Yam EN, Avivi C, Barshack I, Brait M, Sidransky D, Domany E, Rotter V.

Cell Death Differ. 2011 Feb;18(2):271-81. doi: 10.1038/cdd.2010.94. Epub 2010 Aug 6.

18.

Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity.

Cicek M, Fukuyama R, Welch DR, Sizemore N, Casey G.

Cancer Res. 2005 May 1;65(9):3586-95.

19.

Up-regulation of MSX2 enhances the malignant phenotype and is associated with twist 1 expression in human pancreatic cancer cells.

Satoh K, Hamada S, Kimura K, Kanno A, Hirota M, Umino J, Fujibuchi W, Masamune A, Tanaka N, Miura K, Egawa S, Motoi F, Unno M, Vonderhaar BK, Shimosegawa T.

Am J Pathol. 2008 Apr;172(4):926-39. doi: 10.2353/ajpath.2008.070346. Epub 2008 Mar 18.

20.

Loss of breast cancer metastasis suppressor 1 promotes ovarian cancer cell metastasis by increasing chemokine receptor 4 expression.

Sheng XJ, Zhou YQ, Song QY, Zhou DM, Liu QC.

Oncol Rep. 2012 Apr;27(4):1011-8. doi: 10.3892/or.2011.1596. Epub 2011 Dec 19.

Items per page

Supplemental Content

Write to the Help Desk